Heparin Market to Reach a Valuation of US$ 16.3 Billion by the End of 2025

Primitive forms of heparin such as unfractionated heparin (UFH) could have limited bioavailability and variable anticoagulant effect foretold to affect the acceptance and sales of heparin-based products. Adverse effects such as heparin-induced thrombocytopenia (HIT) and hemorrhage could also discourage the adoption of UFH. However, as compared to LMWH and ultra-low molecular weight heparin (ULMWH), the reversal of heparin overdose associated with UFH could be easily achieved using protamine sulfate.

TMR has envisaged the global heparin market to earn an around US$16.3 bn by the end of 2025 while rising at a CAGR of 6.2% during the forecast timeframe 2017-2025. In 2017, the market earned an approximately US$10.1 bn. With respect to segmentation by product, low molecular weight heparin (LMWH) could account for a colossal share in the market by the completion of the forecast period. Regionally, North America has been anticipated to secure a lion’s share while expanding at a 5.6% CAGR.

View Report at https://www.transparencymarketresearch.com/heparin-market.html

Poor yield and the risk of contamination associated with ULMWH have been foreseen to negatively impact its growth in the international heparin market. Moreover, the increased cost of ULMWH owing to chemical-based techniques used for synthesizing and processing could dilute its demand. However, this restraint of the ULMWH market has been expected to be countered with the development of two new methods researched at the University of North Carolina via a series of the bio-enzymatic process. The market could be propelled further with possible price containment because of the emergence of the generic editions of Arixtra.

The world heparin market has been prognosticated to rise aggressively in the foreseeable future due to the rising occurrences of thromboembolic disorders. Since years, heparin has been broadly used as an anticoagulant in the treatment and prevention of such disorders.

Request to View Sample Copy of Report -https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=803

The possible comeback of bovine heparin in the U.S. market by 2022 after reintroduction proposals made by the United States Pharmacopeia (USP) and U.S. Food and Drug Administration (FDA) could raise the hopes of industry players. On the other hand, this could help to address concerns about heparin shortage and adulteration.

After warfarin, heparin is mostly recommended in the treatment for coagulation disorders and during surgical procedures. It is also advisory to administer heparin to patients suffering from transient ischemic attack or stroke and unstable angina.

Inquire for Brochure of the Report:https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=803

Heparin therapy could be used for such patients owing to the quick onset of anticoagulation activity. Increasing cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) have been prophesied to set the tone for a valuable growth in the market. In the U.K., one in every 1,000 individuals is affected by DVT each year, as per the National Health Service (NHS) data.

The global heparin market is prognosticated by Transparency Market Research (TMR) to hold a highly consolidated nature where a number of large global companies and a handful of local players could be operating. The report has studied crucial players such as Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Sanofi, Pfizer, Inc., LEO Pharma A/S, Aspen, Baxter International Inc., B. Braun Melsungen AG, and Syntex S.A.

Global Heparin Market Report is available @ US$ 5795

About TMR 

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact:
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany, NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com 
Research Blog: http://theglobalhealthnews.com/

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.